龍啟生物制藥（immumowake）是一家致力于開發和商業化腫瘤治療的新型雙特異抗體的全球Biotech公司，專注于抗體激活機體免疫、改善腫瘤微環境，治療實體腫瘤的領域。龍啟的目標是開發真正能與西方大藥企匹敵的重磅炸彈藥物，解決臨床未滿足的需求。公司目前已完成A輪融資，美國的研發中心位于伯明翰，中國研發中心位于上海張江藥谷，后期上海將發展成為龍啟制藥的全球研發中心。 龍啟制藥的創始人吳曉云博士是資深的腫瘤免疫治療領域專家、連續創業者。吳博士在美國工作學習三十多年，是一位兼具學術背景、創業經驗并樂于分享的優秀創業者。2021年底，吳博士帶領核心團隊和研發成果以及技術平臺回到中國，開啟中國腫瘤藥出海的新征程。現階段兩個免疫治療雙抗藥物正在積極準備IND申報的資料，預計明年進行中美雙報。希望通過龍啟人的攜手努力，為中國新藥國際化添磚加瓦！ Introduction of Immunowake Biopharmaceutical Co., Ltd Immunowake is a global biotech company committed to developing and commercializing new bispecific antibodies for tumor treatment. It focuses on the field of antibody activating body immunity, improving tumor microenvironment and treating solid tumors. Immunowake's goal is to develop blockbuster drugs that can truly compete with major Western pharmaceutical companies to solve the unmet clinical needs. At present, the company has completed Round A financing. The R & D center in the United States is located in Birmingham, and the R & D center in China is located in Shanghai Zhangjiang Pharmaceutical Valley. Meanwhile, Shanghai will develop into the global R & D center of Immunowake biopharmaceutical. Dr. Xiaoyun Wu , the founder of Immunowake pharmaceutical, is a senior expert and continuous entrepreneur in the field of tumor immunotherapy. Dr. Wu has worked and studied in the United States for more than 30 years. He is an excellent entrepreneur who has both academic background and entrepreneurial experience. At the end of 2021, Dr. Wu led the core team, R & D achievements and technical platform back to China, opening a new journey of Chinese cancer drugs to international market. At this stage, the two immunotherapeutic Bispecific antibodies actively preparing the data of IND declaration, and it is expected that the Sino-US double declaration will be carried out next year. We hope to contribute to the internationalization of Chinese new drugs through the joint efforts of Immunowake Scientists!